179055-21-1

Basic information

• Product Name: 1-Methyl-4-(tributylstannyl)-1H-pyrazole
• Synonyms: 1-Methyl-4-(tributylstannyl)-1H-pyrazole;(1-Methyl-1H-pyrazol-4-yl)tributylstannane;1-Methyl-4-(tributylstannyl)-1H-pyrazole 97%
• CAS NO: 179055-21-1
• Molecular Formula: C₁₆H₃₂N₂Sn
• Molecular Weight: 371.14868
• Mol File: 179055-21-1.mol

Chemical Properties

• Boiling Point: 126-128°C
• Flash Point: 149℃
• Appearance: /
• Density: 1.135 g/mL at 25 °C
• Refractive Index: n20/D1.563
• PKA: 2.25±0.10(Predicted)
• CAS DataBase Reference: 1-Methyl-4-(tributylstannyl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-4-(tributylstannyl)-1H-pyrazole(179055-21-1)
• EPA Substance Registry System: 1-Methyl-4-(tributylstannyl)-1H-pyrazole(179055-21-1)

Safety Data

• Hazard Codes: T,N
• Statements: 21-25-36/38-48/23/25-50/53
• Safety Statements: 35-36/37/39-45-60-61
• RIDADR: UN 2788 6.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 179055-21-1(Hazardous Substances Data)

Usage

Pyrazole derivative

A compound based on the pyrazole structure This indicates that the compound is derived from the pyrazole structure, which is a five-membered heterocyclic ring containing two nitrogen atoms.

Butylstannyl group at the 4-position

A functional group attached to the fourth position of the pyrazole ring This describes the specific location of the butylstannyl group on the pyrazole ring.

Methyl group at the 1-position

A functional group attached to the first position of the pyrazole ring This indicates the presence of a methyl group (a carbon atom with three hydrogen atoms) at the first position of the pyrazole ring.

Organic synthesis

Used in the synthesis of various organic compounds This highlights the compound's role in creating other organic molecules through chemical reactions.

Building block

A starting material for the preparation of other organic compounds This emphasizes the compound's importance as a fundamental component in the synthesis of other molecules.

Biological activities

Exhibits potential antitumor and antifungal properties This refers to the compound's ability to potentially inhibit the growth of tumors and fungi, making it a candidate for further research in these areas.

Upstream product

• 15803-02-8 4-bromo-1-methyl-1H-pyrazole 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 179055-93-7 3-(1-methyl-1H-pyrazol-4-yl)benzaldehyde 
• 179055-29-9 4-(1-methyl-1H-pyrazol-4-yl)benzaldehyde 
• 626605-30-9 3-{1-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-4-(1-methyl-1H-pyrazol-4-yl)-pyrrole-2,5-dione 
• 1392840-07-1 1-benzyl-5-hydroxy-3-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-[1,7]naphthyridine-6-carboxylic acid methyl ester 
• 1665195-94-7 4-(4-(1-methyl-1H-pyrazol-4-yl)-1-(2-(1-methyl-1H-pyrazol-4-yl)ethyl)-1H-imidazol-5-yl)benzonitrile 
• 37921-11-2 1-methyl-4-(4-methylphenyl)-1H-pyrazole 
• 1330740-56-1 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-N-ethyl-4-(1-methyl-1H-pyrazol-4-yl)isoxazole-3-carboxamide 

Relevant articles and documents

METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY

Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type creatine transporter. Also disclosed are methods of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier of a mammal, and methods of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a mammalian cell.

SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein.

METHOD FOR PRODUCING 14 GROUP METAL LITHIUM COMPOUND

PROBLEM TO BE SOLVED: To provide a method for quantitatively producing a group 14 metal lithium compound under a mild condition. SOLUTION: The method for producing a group 14 metal lithium compound represented by formula (4): R4-nMLin comprises reacting a compound represented by formula (1): R4-nMXn and lithium in the presence of a polycyclic aromatic compound represented by formula (2) or formula (3). [In formula (1) and formula (2), R is a hydrocarbon group; M is a metal atom selected from Si, Ge and Sn; X is a halogen atom or R3M- (R and M are the same as mentioned above); and n is 1 or 2] and [R1 is H or a hydrocarbon group; and m is an integer of 0 to 5.] SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Stannyl-Lithium: A Facile and Efficient Synthesis Facilitating Further Applications

We have developed a highly efficient, practical, polycyclic aromatic hydrocarbon (PAH)-catalyzed synthesis of stannyl lithium (Sn-Li), in which the tin resource (stannyl chloride or distannyl) is rapidly and quantitatively transformed into Sn-Li reagent at room temperature without formation of any (toxic) byproducts. The resulting Sn-Li reagent can be stored at ambient temperature for months and shows high reactivity toward various substrates, with quantitative atom efficiency.

Vasopressin agonist formulation and process

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure: and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.

Tricyclic vasopressin agonists

This invention relates to new compounds selected from those of the general formula (I), or a pharmaceutically acceptable salt, ester or prodrug form thereof: wherein D, E and G are N or CH, which serve as vasopressin agonists and are useful in treating disorders such as diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, and the inability to temporarily delay urination and pharmaceutical compositions and methods for same.

Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

γ-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.